PROSTATE CANCER: Combined PD-L1 and multi-kinase inhibition (atezolizumab + cabozantinib) produced ORR 32% in a small (n=44) study of metastatic castrate-resistant disease; two subjects achieved CR (COSMIC-021 trial, ASCO GU 2020).

Web

Feb. 24, 2020

SCIENTIFIC